Resources

Industry Insights

Deep dives on clinical endpoints, regulatory trends and data quality — written and curated by the EClinCloud team.

Chart motif of clinical trial outcome and country multipliers for study-build sizingDeep Research41 min readClinical Trial Protocol Complexity 2026: Endpoints, Multicenter Countries and Study-Build Workload on ClinicalTrials.govPublic protocol files store outcome, group, country and facility multipliers, not EDC hours. Median studies are small; Phase 3 industry interventional trials sit on a different build surface.Illustration of clinical outcome assessment types missing from public trial registry textDeep Research40 min readFDA PFDD Guidance 3 and ClinicalTrials.gov 2026: PRO vs ClinRO Tokens, Patient-Reported Outcome Registration, and eCOA ImplementationFDA PFDD Guidance 3 is a fit-for-purpose selection file. ClinicalTrials.gov outcome text almost never stores COA type; PRO language is common and still not validation.Illustration of FDA BIMO record citations versus computerized-system keyword hitsDeep Research40 min readFDA Warning Letters, BIMO Computerized Systems and 21 CFR 312.62 Records in 2026: What Clinical Trial Data Integrity, Part 11 and eTMF Inspections Actually CiteFDA warning letters and BIMO observations cite investigator records and protocol compliance far more than EDC or eTMF products. Part 11 is not the dominant public inspection object.Diagram of four public trial-register identity fields that do not join as one rowDeep Research38 min readCTIS vs ClinicalTrials.gov vs China CTR: What a Failed WHO ICTRP Join Means in 2026ClinicalTrials.gov, CTIS, China Drug Trials and WHO ICTRP use different identity contracts. A failed NCT-CT number-CTR join is usually the key, not proof the study is unregistered.Football video review used as an analogy for independent imaging reviewInsight3 min readWhy decisive imaging endpoints need an independent second lookWhat independent central imaging review adds to multicenter trials, when sponsors should introduce IRC, and how a connected platform keeps imaging endpoints reliable.Illustration for an overview of ICH E6(R3)Insight3 min readICH E6(R3): Clinical trials enter the era of risk-driven digital governanceWhat ICH E6(R3) changes for digital trial technology, risk-based quality management, data governance, and the systems sponsors use to keep evidence reliable.Illustration for FDA clinical outcome assessment guidanceInsight3 min readFrom regulatory intent to practice: choosing a fit-for-purpose clinical outcome assessmentA practical overview of FDA PFDD Guidance 3, the four COA types, fit-for-purpose evidence, and how eCOA supports patient-focused endpoint implementation.